Aricept holds up for Eisai in first half
This article was originally published in Scrip
Good growth for mainstay product Aricept (donepezil), particularly in the US, helped push Eisai's group net sales up by 4% to ¥412.3 billion ($5.07 billion) in the first half ended 30 September.
You may also be interested in...
Positive clinical results pave path forward for Japanese firm’s potential istradefylline successor.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.